Stanford researchers make lung cancer finging that could vastly improve treatment and outcome

STANFORD, Calif. - Researchers at the Stanford University Medical Center have uncovered a group of genes that could distinguish between different forms of lung cancer. This finding may help doctors predict individual treatment strategies and may someday lead to better lung cancer drugs.

"What this means is that we can distinguish between different types of lung cancers, which was not possible before, and that those differences have clinical consequences," said David Botstein, MD, professor of genetics and senior author on the study, published in the Proceedings of the National Academy of Sciences on Nov. 13.

Doctors currently categorize lung tumors into one of four types: small cell, squamous cell, large cell and adenocarcinoma. When doctors diagnose a small-cell tumor, they can provide a fairly accurate prognosis. But other tumor types, particularly adenocarcinomas, respond very differently to standard treatment.

"Lung adenocarcinomas may appear morphologically similar, however, the patients differ in survival and possibly drug sensitivity," said Mitchell Garber, a post-doctoral student and first author on the paper. "At present, the pathologist cannot determine patient survival for those diagnosed with adenocarcinoma."

Garber thought these differences may arise from gene variations within the tumor. If that's the case, doctors would have an additional tool for distinguishing how tumors will grow, helping to determine the best course of treatment for each patient. "The short-term goal is to know the fingerprint of a tumor that has a poor prognosis," Garber said. "That will give the clinician an incentive to look a little harder within this patient for additional tumors."

To find out whether genetic differences exist between lung tumors, Garber obtained RNA from 67 lung tumor samples and six normal lung samples. RNA is produced by active genes and can be used to identify which genes are being expressed in a given sample. He t

Contact: Sheila Foster
Stanford University Medical Center

Page: 1 2 3

Related biology news :

1. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
2. Stanford researchers findings may shed light on common, deadly birth defect
3. Leukemia stem cells identified by Stanford researchers
4. New view of leukemia cells identifies best treatment options, Stanford researchers say
5. Confidentiality of genetic databases questioned by Stanford researchers
6. Stanford researchers go from heaven to Earth in lifeguard test
7. Transplant rejection averted by simple light exposure in Stanford animal study
8. Fat cells heal skull defects in mice, Stanford research shows
9. Gene-based screen sorts cancer cases, say Stanford researchers
10. Elusive but ubiquitous microbe fingered as gum disease culprit in Stanford study
11. Sticklebacks reveal secrets to evolutionary change in Stanford study

Post Your Comments:

(Date:1/7/2020)... ... January 07, 2020 , ... ... Lifecycle prospectus features not just part numbers like what can be found in ... industries it supports, and that is all linked to the impact it has ...
(Date:1/2/2020)... ... January 02, 2020 , ... ... reagents, chemicals, and medias, as well as medical grade plastic products to the ... product manufacturers. , “We are excited to bring even more advantages and ...
(Date:12/30/2019)... (PRWEB) , ... December 30, 2019 , ... ... the Alzheimer’s Association:, ,     Alzheimer's disease is the 6th leading ... Americans provide unpaid care for people with Alzheimer's or other dementia. , ...
Breaking Biology News(10 mins):
(Date:1/28/2020)... ... January 28, 2020 , ... Lifecycle Biotechnologies announced ... beverage manufactures within North America. Both Lifecycle and Midland have supported this industry ... company to pool their collective resources and provide the industry with support, service, ...
(Date:1/27/2020)... (PRWEB) , ... January 27, 2020 , ... ... announced it has secured financing from strategic investors led by Halma plc ... from existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A ...
(Date:1/23/2020)... ... 22, 2020 , ... Ideal Implant CEO and President Robert ... recent North American investor forums specializing in medical advancements. New technology was presented ... Forum on November 21, 2019 in New York City, and the Aesthetic Technology ...
(Date:1/22/2020)... ... January 21, 2020 , ... QCDx , a ... from a simple blood draw, today announced the sale of the proprietary RareScope™ instrument ... Scope will be used in clinical cancer research. , “The RareScope can detect and ...
Breaking Biology Technology:
Cached News: